PPP2R3B Antibody

What is PPP2R3B and why is it significant in cellular research?

PPP2R3B encodes PR70, a regulatory unit of the critical phosphatase PP2A. This gene has gained significant research interest due to its role in melanocytic neoplasia, where germline duplications have been associated with melanoma and melanocytic nevi development. PR70 appears to influence cellular phenotype switching, promoting proliferation while reducing migration, which may explain its connection to melanocytic conditions . Research involving PPP2R3B antibodies is essential for studying protein expression levels and interactions in various cellular contexts.

What validation methods should be used for PPP2R3B antibodies?

Proper validation of PPP2R3B antibodies is crucial for experimental reliability. Based on current research practices, antibody validation should include CRISPR/Cas9 knockout controls to confirm specificity. As demonstrated in recent studies, researchers successfully validated PR70 antibodies using CRISPR/Cas9 knockout techniques to ensure antibody specificity before conducting extensive immunohistochemistry and western blot analyses . Additionally, testing across multiple cell lines (such as SKMEL2 and SKMEL30) is recommended to account for potential cell type-specific variations in epitope presentation.

How can immunohistochemistry protocols be optimized for PPP2R3B antibody use in tissue samples?

For optimal PPP2R3B/PR70 detection in tissue samples:

• Tissue preparation: Use standard formalin fixation and paraffin embedding, ensuring consistent fixation times (12-24 hours) to maintain protein antigenicity

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) at 95-98°C for 20-30 minutes

• Primary antibody: Apply PPP2R3B antibody at optimized dilution (typically 1:100 to 1:500) determined through titration experiments

• Detection system: Use a sensitive detection system with minimal background (e.g., polymer-based systems)

• Controls: Include positive controls (tissues known to express PPP2R3B) and negative controls (omitting primary antibody)

• Counterstain: Use hematoxylin for nuclear visualization

Research demonstrates that careful optimization allows clear visualization of PR70 expression differences between samples with and without PPP2R3B duplications .

How can inducible expression systems be designed to study PPP2R3B function and antibody validation?

Creating stable inducible PPP2R3B expression systems involves these critical methodological steps:

• Cloning preparation:

  • Linearize the human myc-FLAG tagged PPP2R3B ORF clone

  • Amplify insert DNA using modified primers to generate an N-terminal Myc tag

  • Use directional cloning systems (e.g., In-Fusion® HD Cloning) for insertion into a lentiviral vector system

• Vector construction:

  • Clone the PPP2R3B insert into the lentiviral vector (e.g., pTRIPZ) at specific restriction sites (AgeI-MluI)

  • Remove non-essential vector elements (TurboRFP, shRNAmir) if necessary

• Lentiviral transduction:

  • Transduce HEK 293T cells with the vector construct plus packaging plasmids (psPAX2 and pMD2.G)

  • Collect viral particles and use them to infect target cells (e.g., SKMEL2, SKMEL30)

  • Enhance infection efficiency with polybrene

  • Select stable cell lines using puromycin

This system allows controlled PPP2R3B expression for studying protein function and provides excellent antibody validation opportunities by comparing induced vs. non-induced samples .

What approaches resolve discrepancies between PPP2R3B protein and mRNA expression levels?

When faced with discrepancies between PPP2R3B protein and mRNA expression levels, researchers should implement a multi-faceted approach:

• Technical validation:

  • Confirm antibody specificity through knockout controls and multiple antibodies targeting different epitopes

  • Validate RNA quantification methods using multiple reference genes

  • Employ absolute quantification methods (digital PCR) for more precise measurements

• Biological investigations:

  • Examine post-transcriptional regulation by analyzing microRNA targeting PPP2R3B

  • Investigate protein stability using cycloheximide chase assays to determine half-life

  • Assess proteasomal degradation pathways using inhibitors (MG132)

  • Analyze contextual differences that might affect translation efficiency

• Time-course experiments:

  • Perform synchronized measurements of mRNA and protein at multiple timepoints

  • Consider delays between transcription and translation

Research indicates that the ratio of PR70 to core PP2A enzyme is critical, suggesting complex regulation beyond simple expression levels that may explain observed discrepancies .

How can PPP2R3B antibodies be used to assess phenotype switching in melanoma cells?

PPP2R3B antibodies play a critical role in studying phenotype switching in melanoma cells through these methodological approaches:

• Immunoblotting for pathway analysis:

  • Use PPP2R3B antibodies to quantify PR70 expression levels

  • Simultaneously probe for markers of proliferation (e.g., Ki67, PCNA)

  • Assess migration markers (e.g., cadherins, integrins)

  • Correlate PR70 levels with signaling pathway activation (AKT, mTOR)

• Immunocytochemistry for spatial analysis:

  • Use PPP2R3B antibodies to visualize PR70 subcellular localization

  • Perform co-localization studies with proliferation and migration markers

  • Analyze morphological changes associated with different PR70 expression levels

• Time-course analysis following induction:

  • In inducible systems, collect samples at multiple timepoints (6-8 hours, 24 hours, 48 hours)

  • Use PPP2R3B antibodies to confirm protein expression kinetics

  • Correlate with phenotypic changes in proliferation and migration

Research has established that PPP2R3B overexpression drives pigment cell phenotype switching toward proliferation and away from migration, which can be effectively monitored using these antibody-based techniques .

What are the optimal protocols for using PPP2R3B antibodies in Reverse Phase Protein Arrays (RPPA)?

For optimal use of PPP2R3B antibodies in RPPA analysis:

• Sample preparation:

  • Harvest cells in lysis buffer containing phosphatase inhibitors

  • Standardize protein concentration (1-2 μg/μl)

  • Prepare serial dilutions to ensure linear detection range

• Array printing:

  • Print samples on nitrocellulose-coated slides in technical replicates

  • Include positive and negative controls on each array

  • Use robotic spotters for consistent spot morphology

• PPP2R3B antibody optimization:

  • Perform antibody titration to determine optimal concentration

  • Validate specificity using western blot correlation

  • Test for cross-reactivity with related phosphatase regulatory subunits

• Signal detection and analysis:

  • Use fluorescent secondary antibodies for quantitative detection

  • Normalize signals to total protein stains

  • Compare PPP2R3B/PR70 levels with other signaling proteins (302 proteins typically analyzed)

RPPA has been successfully used to characterize signaling pathway alterations following PPP2R3B induction, identifying enrichment for mTOR and HIF-1 signaling pathways .

How can researchers overcome challenges in detecting low-abundance PPP2R3B protein in tissue samples?

When facing challenges detecting low-abundance PPP2R3B/PR70:

• Sample enrichment strategies:

  • Perform subcellular fractionation to concentrate relevant compartments

  • Use immunoprecipitation to concentrate PR70 before western blotting

  • Apply tyramide signal amplification for immunohistochemistry

• Technical optimizations:

  • Use high-sensitivity detection substrates (e.g., SuperSignal West Femto)

  • Increase antibody incubation time (overnight at 4°C)

  • Optimize protein extraction with specialized buffers containing phosphatase inhibitors

  • Consider alternative antibodies targeting different epitopes

• Control strategies:

  • Include positive controls with known PPP2R3B overexpression

  • Use induced cells from stable expression systems as standards

  • Apply recombinant PR70 protein as a reference standard

These approaches have proven effective in research contexts where detecting subtle differences in PR70 expression was critical for studying its role in melanocytic neoplasia .

How should researchers interpret contradictory results between different PPP2R3B antibodies?

When faced with contradictory results between different PPP2R3B antibodies:

• Epitope mapping analysis:

  • Determine the specific epitopes recognized by each antibody

  • Assess whether post-translational modifications might affect epitope recognition

  • Consider potential protein isoforms that might be differentially recognized

• Validation hierarchy establishment:

  • Prioritize antibodies validated by knockout/knockdown controls

  • Compare results with transcriptomic data when available

  • Consider orthogonal detection methods (mass spectrometry)

• Experimental context evaluation:

  • Assess whether specific experimental conditions might affect epitope accessibility

  • Examine buffer compositions and fixation methods

  • Consider protein-protein interactions that might mask epitopes

• Dose-response assessment:

  • Analyze whether contradictions might reflect different sensitivities rather than specificity issues

  • Perform titration experiments with both antibodies

Research has demonstrated that the ratio of PR70 to core PP2A enzyme is critical for function, suggesting that different antibodies might detect different conformational states or complexes of the protein .

How can researchers use PPP2R3B antibodies to investigate its relationship with C21orf91 in phenotype switching?

To investigate the PPP2R3B-C21orf91 relationship in phenotype switching:

• Co-expression analysis:

  • Use PPP2R3B antibodies alongside C21orf91 antibodies in western blots

  • Perform time-course studies following PPP2R3B induction to track C21orf91 expression

  • Quantify correlation between expression levels in various experimental conditions

• Functional studies with combined molecular techniques:

  • Induce PPP2R3B expression while simultaneously performing C21orf91 siRNA knockdown

  • Use PPP2R3B antibodies to confirm induction efficiency

  • Measure proliferation via IncuCyte® or BrdU assays

  • Assess migration using scratch wound assays

• Interaction analysis:

  • Perform co-immunoprecipitation with PPP2R3B antibodies to identify potential interactions

  • Use proximity ligation assays to detect close association in situ

  • Consider chromatin immunoprecipitation to examine potential transcriptional regulation

Research has established that PPP2R3B overexpression leads to significant and sustained increase in C21orf91 expression, and C21orf91 knockdown rescues both the increased proliferation and decreased migration associated with PPP2R3B induction .

What methodologies can assess the relationship between PPP2R3B expression and melanoma-specific survival?

To investigate the relationship between PPP2R3B expression and melanoma-specific survival:

• Tissue microarray analysis:

  • Prepare tissue microarrays from melanoma samples with known clinical outcomes

  • Perform immunohistochemistry using validated PPP2R3B antibodies

  • Quantify expression using digital pathology tools

  • Correlate with survival data using Kaplan-Meier analysis

• Multi-parameter analysis:

  • Include correction for known prognostic factors:

    • Age

    • Sex

    • AJCC stage

    • Vascular invasion

    • Site

    • BRAF/NRAS mutation status

    • Tumor-infiltrating lymphocytes (TILs)

• Mechanism investigation:

  • Assess correlation with immune markers to rule out immunological mechanisms

  • Analyze relationship with proliferation and migration markers

  • Examine C21orf91 expression correlation with survival

Research has demonstrated that increased PPP2R3B expression correlates with prolonged melanoma-specific survival through a non-immunological mechanism, potentially related to phenotype switching toward proliferation and away from migration .